The UK generics industry has been waiting for over a year to find out what the CMA’s final decision would be on the Pfizer/Flynn phenytoin case, following its preliminary ruling in August 2015 that the two companies were guilty of abuse of a dominant...
And in the blue corner: Valeant
The great thing about takeover battles in the US is that they are so much more interesting than they are in the UK. In contrast to the polite press releases that accompanied Pfizer’s recent unsuccessful attempt to buy AstraZeneca, Valeant’s ongoing efforts to get...
Teva and Amgen settle over G-CSF, but Teva still has hard work ahead
It was announced on Friday that Teva and Amgen have settled their patent litigation over Neupogen (G-CSF) and Neulasta (PEG G-CSF), with Amgen agreeing that Teva can launch its products on 10th November 2013, or earlier if another company’s biosimilar is approved before then....
Nice try: Mylan sues the FDA in an effort to overturn Ranbaxy’s exclusivity on Lipitor
It was revealed today that Mylan has filed suit at the Washington District Court in an effort to get the FDA to withdraw Ranbaxy’s first-to-file (FTF) status for its generic version of Pfizer’s blockbuster anti-cholesterol drug, Lipitor (atorvastatin), and hence to rescind Ranbaxy’s 180...
Sun wins Taro – at last
The Israeli Supreme Court today ruled in favour of Sun Pharmaceuticals and so at last brought to an end its long-running dispute with the controlling shareholders of Taro Pharmaceuticals. Sun has been trying to take over Taro since May 2007, when it emerged the...
Protonix court ruling raises prospect of fines for Teva and Sun
The US District Court of New Jersey ruled today that Nycomed’s patent on Protonix, no. 4,758,579, is not invalid, although Teva is still trying to argue that the patent, while valid, should never have been granted due to obviousness-type double patenting. Teva launched a...